Review: Infliximab increases response and remission rates in fistulizing or treatment-resistant Crohn diseasePDF
ACP J Club. 2002 Nov-Dec;137:91. doi:10.7326/ACPJC-2002-137-3-091
Marshall JK, Blackhouse G, Goeree R, et al. Infliximab for the treatment of Crohn’s disease: a systematic review and cost-utility analysis. Technology report no. 24. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2002. www.ccohta.ca. (All 2002 articles were reviewed for relevancy, and abstracts were last revised in 2008.)
In patients with fistulizing or treatment-resistant Crohn disease, is infliximab safe and effective?
Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, Current Contents, CINAHL, HealthSTAR, TOXLINE, the Cochrane Library, Drug Info Full Text, Pharmaceutical & Health Care Industry News, PharmaProjects, and Pharmaceutical News Index (1990 to May 2001). Scientific meeting abstracts were searched; major clinical gastroenterology journals were hand searched (to August 2001); and authors, government agencies, and pharmaceutical companies were contacted.
2 reviewers independently selected English-language randomized controlled trials (RCTs) that reported clinical end points for infliximab treatment in adults with fistulizing or treatment-resistant Crohn disease.
2 independent reviewers extracted data on study centers, source of funding, patients, treatment regimens, quality of study methods, and outcomes (response, remission, and fistula closure).
4 RCTs met the selection criteria. Fistulizing Crohn disease: 1 RCT (n = 94) showed that more patients in the infliximab groups than in the placebo group had ≥ 50% closure (Table). Treatment-resistant Crohn disease: RCTs of treatment-resistant Crohn disease were too heterogeneous to be combined. The Table shows the 4-week and 12-week results for 1 RCT (n = 108); in responders, reinfusions of 10-mg infliximab at 8-week intervals led to more remissions (44% vs 20%, P = 0.013) at 44 weeks than did placebo, but the difference in response rate was not statistically significant (62% vs 37%, P = 0.16). The interim 30-week results for 1 RCT (n = 335) still in progress showed a benefit for maintenance 5-mg or 10-mg infliximab (Table). Data from controlled clinical trials showed that serious adverse events occurred in 13% of patients treated with infliximab and 4% of patients treated with placebo.
In patients with fistulizing or treatment-resistant Crohn disease, infliximab increases remission and response rates.
Source of funding: Not stated.
For correspondence: Dr. J.K. Marshall, McMaster University, Hamilton, Ontario, Canada. E-mail firstname.lastname@example.org.
Table. Infliximab (inflix) for Crohn disease (CD)*
|Patient group||Outcomes||Number of patients||Dose||Inflix||Placebo||RBI (95% CI)||NNT (CI)|
|Fistulizing CD||≥ 50% closure at 18 wk||94||5 mg, 10 mg||62%||26%||140% (37 to 363)||3 (2 to 7)|
|Treatment-resistant CD||Response at 4 wk||108||5 mg, 10 mg, 20 mg||65%||16%||307% (84 to 928)||3 (2 to 4)|
|Response at 12 wk||108||5 mg, 10 mg, 20 mg||41%||12%||241% (31 to 908)||3 (2 to 12)|
|Remission at 12 wk||108||5 mg, 10 mg, 20 mg||24%||8.0%||201% (−10 to 10)||Not significant|
|Repeat doses||Single dose|
|Response at 30 wk†||335||5 mg,10 mgvs 5 mg||55%||27%||102% (48 to 183)||4(3 to 6)|
|Remission at 30 wk†||335||5 mg, 10 mg vs 5 mg||42%||21%||100% (37 to 199)||5 (4 to 10)|
*Abbreviations defined in Glossary; RBI, NNT, and CI calculated from data in article.
†Interim data reported from a 102-week ongoing trial of maintenance infliximab.
Marshall and colleagues have systematically reviewed the new, interesting topic of treating Crohn disease with infliximab (a chimeric human–murine monoclonal antibody against the proinflammatory cytokine tumor-necrosis factor–α) and the economic effect of this treatment. The percentage of improvement in patients who received infliximab in all of the studies is impressive, and no doubts exist about its effectiveness in either fistulizing or refractory disease. A recent trial by Hanauer and colleagues (1) also encourages use of this drug for inducing and maintaining clinical remission in patients with Crohn disease. The high cost of the treatment might be balanced, at least in part, by a substantial improvement in the quality of life of the patients.
The trials on infliximab suggest that large, serious, and rarely life-threatening side effects, such as acute infusion reactions, human antichimeric antibodies, autoimmune disorders, malignancy, and infection (i.e., tuberculosis and intestinal strictures), may result from this treatment. A causal association for some of these side effects is not established yet, but no doubt exists that this very potent drug must be managed with great care. The long-term follow-up will help us better understand the potential and proper use of this new agent. In the meantime, treatment with infliximab should be offered to a select subgroup of patients with Crohn disease in whom the need of more effective treatment for severe, persevering, and life-limiting symptoms is balanced with the risk for potentially serious side effects.
Andrea Belluzzi, MD
S. Orsola Hospital
1. Hanauer SB, Feagan BG, Lichtenstein GR, et al, for the ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-49. [PubMed ID: 12047962]